CURx picks up a Gilead cystic fibrosis drug ready for Phase III

Damian Garde

San Diego startup has paid an undisclosed sum to license an antiobitic developed by , planning to launch a III trial on the to treat lung infections in patients. 

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS